AMGN:NSD-Amgen Inc (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 319.22

Change

0.00 (0.00)%

Market Cap

USD 171.59B

Volume

1.83M

Analyst Target

USD 262.76
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Address: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-03 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

N/A

USD 221.82B
SNY Sanofi ADR

N/A

USD 136.24B
GILD Gilead Sciences Inc

N/A

USD 111.44B
BIIB Biogen Inc

N/A

USD 25.32B
GRFS Grifols SA ADR

N/A

USD 6.92B
AMRN Amarin Corporation PLC

N/A

USD 0.24B
MIRA MIRA Pharmaceuticals, Inc. Com..

N/A

USD 0.03B
SCLX Scilex Holding Company

N/A

N/A
SCLXW Scilex Holding Company

N/A

N/A

ETFs Containing AMGN

BBH VanEck Biotech ETF 16.72 % 0.35 %

N/A

USD 0.43B
BIS ProShares UltraShort Nasd.. 8.14 % 0.95 %

N/A

USD 3.52M
IBBQ Invesco Nasdaq Biotechnol.. 8.07 % 0.00 %

N/A

USD 0.04B
2B70:F iShares NASDAQ US Biotech.. 8.06 % 0.00 %

N/A

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 8.06 % 0.00 %

N/A

USD 0.52B
BTEC:SW iShares Nasdaq US Biotech.. 7.89 % 0.00 %

N/A

N/A
UBIO 6.41 % 0.95 %

N/A

N/A
MEDX Horizon Kinetics Medical .. 5.91 % 0.00 %

N/A

N/A
BIB ProShares Ultra Nasdaq Bi.. 5.49 % 0.95 %

N/A

USD 0.08B
LIFE-B:CA Evolve Global Healthcare .. 5.45 % 0.00 %

N/A

N/A
ZWA:CA BMO Covered Call Dow Jone.. 5.39 % 0.72 %

N/A

CAD 0.21B
ZDJ:CA BMO Dow Jones Industrial .. 5.33 % 0.26 %

N/A

CAD 0.43B
ZWHC:CA BMO Covered Call Health C.. 5.07 % 0.00 %

N/A

N/A
THNR Amplify ETF Trust 5.05 % 0.00 %

N/A

USD 4.67M
SXRU:F iShares Dow Jones Indust .. 5.02 % 0.00 %

N/A

USD 1.24B
CSINDU:SW iShares VII PLC - iShares.. 4.99 % 0.00 %

N/A

USD 1.22B
EXI3:XETRA iShares Dow Jones Industr.. 4.97 % 0.00 %

N/A

USD 0.30B
NDJI 4.95 % 0.00 %

N/A

N/A
LIFE-U:CA Evolve Global Healthcare .. 4.94 % 0.00 %

N/A

N/A
DJIA Global X Dow 30 Covered C.. 4.94 % 0.00 %

N/A

USD 0.09B
YALL God Bless America ETF 4.70 % 0.00 %

N/A

N/A
DIVO Amplify CWP Enhanced Divi.. 4.64 % 0.94 %

N/A

USD 3.65B
GDOC Goldman Sachs ETF Trust 4.59 % 0.00 %

N/A

USD 0.02B
DOGG 4.41 % 0.00 %

N/A

N/A
CBUF:F iShares V Public Limited .. 4.40 % 0.00 %

N/A

N/A
WHCS:SW iShares MSCI World Health.. 4.21 % 0.00 %

N/A

N/A
XDG3:XETRA Xtrackers MSCI Global SDG.. 4.20 % 0.00 %

N/A

USD 0.14B
FTXH First Trust Nasdaq Pharma.. 3.57 % 0.60 %

N/A

USD 0.02B
ESGI:AU VanEck MSCI International.. 3.51 % 0.00 %

N/A

USD 0.19B
WH2E:XETRA Invesco Markets II plc - .. 3.35 % 0.00 %

N/A

USD 0.07B
OZEM Roundhill GLP-1 & Weight .. 3.27 % 0.00 %

N/A

USD 0.05B
AGNG Global X Aging Population.. 3.19 % 0.00 %

N/A

USD 0.06B
FDV First Trust Capital Stren.. 3.17 % 0.00 %

N/A

N/A
IUHC:SW iShares S&P 500 Health Ca.. 3.12 % 0.00 %

N/A

N/A
GXLV:LSE SPDR® S&P® U.S. Health .. 3.11 % 0.00 %

N/A

N/A
XLV Health Care Select Sector.. 3.07 % 0.13 %

N/A

USD 40.26B
ZPDH:F SPDR S&P U.S. Health Care.. 3.06 % 0.00 %

N/A

USD 0.40B
SXLV:SW SPDR S&P U.S. Health Care.. 3.06 % 0.00 %

N/A

N/A
XSHC:LSE Xtrackers MSCI USA Health.. 3.00 % 0.00 %

N/A

USD 0.65B
XUHC:LSE Xtrackers MSCI USA Health.. 3.00 % 0.00 %

N/A

USD 0.65B
HEAL:CA 2.96 % 0.00 %

N/A

N/A
XUHC:F Xtrackers (IE) Public Lim.. 2.95 % 0.00 %

N/A

USD 0.85B
XUHC:SW Xtrackers MSCI USA Health.. 2.95 % 0.00 %

N/A

USD 0.65B
NZRO 2.90 % 0.00 %

N/A

N/A
UDOW ProShares UltraPro Dow30 2.49 % 0.95 %

N/A

USD 0.65B
UVDV 2.35 % 0.00 %

N/A

N/A
USRI:LSE 1.80 % 0.00 %

N/A

N/A
ZUH:CA BMO Equal Weight US Healt.. 1.76 % 0.39 %

N/A

CAD 0.26B
DSTL Distillate US Fundamental.. 1.76 % 0.00 %

N/A

USD 2.00B
XLVE:CA Mulvihill U.S. Health Car.. 1.72 % 0.00 %

N/A

N/A
ZDY.U:CA 1.63 % 0.33 %

N/A

N/A
HYLG Global X Funds - Global X.. 1.45 % 0.00 %

N/A

N/A
LESW:LSE 1.25 % 0.00 %

N/A

N/A
XAMB:F Amundi Index Solutions - .. 1.14 % 0.00 %

N/A

N/A
SF1CHA:SW 1.09 % 0.00 %

N/A

N/A
F1ESG:SW UBS(Lux)Fund Solutions .. 1.09 % 0.00 %

N/A

N/A
CURE Direxion Daily Healthcare.. 0.00 % 1.06 %

N/A

USD 0.17B
DDM ProShares Ultra Dow30 0.00 % 0.95 %

N/A

N/A
DEW WisdomTree Global High Di.. 0.00 % 0.58 %

N/A

N/A
DIA SPDR Dow Jones Industrial.. 0.00 % 0.17 %

N/A

N/A
DJD Invesco Dow Jones Industr.. 0.00 % 0.09 %

N/A

N/A
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

N/A

N/A
FHLC Fidelity® MSCI Health Ca.. 0.00 % 0.08 %

N/A

USD 2.86B
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 7.19B
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

N/A

N/A
LABS 0.00 % 0.45 %

N/A

N/A
LNGR 0.00 % 0.50 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

N/A
HONR 0.00 % 0.65 %

N/A

N/A
VSL 0.00 % 0.65 %

N/A

N/A
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

N/A

CAD 0.01B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

N/A
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

N/A

N/A
SICK 0.00 % 0.95 %

N/A

N/A
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

N/A

N/A
HHL:CA Harvest Healthcare Leader.. 0.00 % 1.15 %

N/A

N/A
CIND:LSE iShares VII PLC - iShares.. 0.00 % 0.00 %

N/A

USD 1.22B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

N/A
IUHC:LSE iShares S&P 500 USD Healt.. 0.00 % 0.00 %

N/A

USD 2.66B
SXLV:LSE SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

N/A

N/A
VMVL:LSE 0.00 % 0.00 %

N/A

N/A
WQDS:LSE iShares MSCI World Qualit.. 0.00 % 0.00 %

N/A

N/A
WQDV:LSE iShares MSCI World Qualit.. 0.00 % 0.00 %

N/A

N/A
XLDX:LSE Xtrackers LevDAX Daily Sw.. 0.00 % 0.00 %

N/A

N/A
EXI3:F iShares Dow Jones Industr.. 0.00 % 0.00 %

N/A

N/A
GNAR:F 0.00 % 0.00 %

N/A

N/A
MJMT:F Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

N/A
QDVG:F iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

N/A
QDVW:F iShares MSCI World Qualit.. 0.00 % 0.00 %

N/A

N/A
GNAR:XETRA 0.00 % 0.00 %

N/A

N/A
QDVG:XETRA iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

USD 2.05B
SXRU:XETRA iShares VII PLC - iShares.. 0.00 % 0.00 %

N/A

USD 1.16B
VMVL:XETRA 0.00 % 0.00 %

N/A

N/A
XUHC:XETRA Xtrackers MSCI USA Health.. 0.00 % 0.00 %

N/A

USD 0.85B
ZPDH:XETRA SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

N/A

USD 0.40B
1546:TSE NEXT FUNDS DJIA (Yen-UnHe.. 0.00 % 0.00 %

N/A

USD 19.52B
TQGD:CA TD Q Global Dividend ETF 0.00 % 0.00 %

N/A

CAD 0.19B
NUSA:CA NBI Active U.S. Equity ET.. 0.00 % 0.00 %

N/A

CAD 0.06B
OUFH:XETRA 0.00 % 0.00 %

N/A

N/A
HLTH:AU VanEck Global Healthcare .. 0.00 % 0.00 %

N/A

USD 0.06B
ESNG 0.00 % 0.00 %

N/A

N/A
CBUF:XETRA iShares MSCI World Health.. 0.00 % 0.00 %

N/A

USD 1.13B
WELG:XETRA Amundi S&P Global Health .. 0.00 % 0.00 %

N/A

N/A
WELS:XETRA Amundi S&P Global Health .. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.83% 80% B- 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.83% 80% B- 60% D-
Trailing 12 Months  
Capital Gain 18.29% 80% B- 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.29% 80% B- 57% F
Trailing 5 Years  
Capital Gain 48.42% 100% F 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 48.42% 100% F 69% C-
Average Annual (5 Year Horizon)  
Capital Gain 7.53% 90% A- 58% F
Dividend Return 10.55% 100% F 61% D-
Total Return 3.03% 60% D- 66% D+
Risk Return Profile  
Volatility (Standard Deviation) 14.44% 80% B- 85% B
Risk Adjusted Return 73.08% 90% A- 89% A-
Market Capitalization 171.59B 88% B+ 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.